Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024  - Episode 14

Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

, , , ,

Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.

EP. 1: Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification
EP. 2: Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 
EP. 3: Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies
EP. 4: Review of the COMMANDS Trial
EP. 5: Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial
EP. 6: Clinical Implications of COMMANDS Trial in Clinical Practice
EP. 7: Treatment Decision-Making Based on the COMMANDS Trials
EP. 8: Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024
EP. 9: Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data
EP. 10: Safety Profile of Available Frontline Treatments LR-MDS
EP. 11: 1L treatment of lower-risk MDS beyond luspatercept
EP. 12: Sequencing Second-Line Treatments for LR-MDS
EP. 13: Perspectives of IMerge Study
Now Viewing
EP. 14: Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024
EP. 15: EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates
EP. 16: Final Thoughts on EHA 2024 Data for Lower-Risk MDS
  1. Focusing on real-world evidence (RWE), how do outcomes compare what’s seen in practice and how does that impact your choice of therapy?
    1. Real-world dose escalation and outcomes of luspatercept across all LOTs (Patel K, et al. EHA 2024. Abstract P768.)
    2. IMerge study, PROs in heavily pre-treated patients with LR-MDS: Sekeres MA, et al. Blood. 2023; 142 (suppl 1):6479.
    3. Real World Data Replicates Medalist Study Results (Komrokji RS et al. Blood 2022)
  2. Can each of you share any key takeaways or additional data updates surrounding lower-risk MDS presented at EHA 2024? (if time permits)
  3. Let’s discuss novel agents and/or combination strategies in LR-MDS through ongoing research that may shape the future treatment landscape.
    1. Luspatercept plus erythropoietin in LR-MDS: Jonasova A, et al. EHA 2024. Abstract P1886.
    2. Luspatercept plus ESA combinations in LR-MDS: Komrokji RS, et al. Blood Adv. 2023.
    3. Ph 2 study, elritercept (KER-050): Díez Campelo M, et al. EHA 2024. Abstract S183.